In a patient taking temazepam 15 mg as needed, trazodone 25 mg nightly, hydroxyzine 25 mg every eight hours (daily use), diazepam 5 mg twice daily, and vortioxetine (Trintellix) 20 mg daily, who reports severe anxiety (10/10) and progressive vision loss and requests higher medication doses, what is the safest pharmacologic management plan?

Do Not Escalate Doses—Focus on Benzodiazepine Deprescribing and Addressing Underlying Issues

Your patient is on dangerous polypharmacy with two benzodiazepines (temazepam PRN and diazepam 10 mg/day total) plus hydroxyzine being used daily, creating significant risk for cognitive impairment, falls, and addiction—you should refuse dose escalation and instead initiate a gradual benzodiazepine taper while addressing his vision loss and possible underlying depression. 1

Why Escalation is Harmful

Your patient's medication regimen represents exactly what guidelines warn against:

• Benzodiazepines cause the anxiety they're meant to treat when used chronically. The cognitive impairment, reduced mobility, and functional decline associated with benzodiazepines 1 likely worsen his distress about vision loss
• Current consensus guidelines advise benzodiazepine use solely on a short-term basis 1—your patient is on chronic dual benzodiazepine therapy (temazepam + diazepam)
• Adding hydroxyzine daily (essentially a third sedating agent) compounds the problem
• His "10/10 anxiety always" despite maximum polypharmacy proves this approach has failed

The Real Problem: Vision Loss and Possible Medication-Induced Worsening

Critical consideration: Psychotropic medications can cause ocular adverse effects 2. While his vision loss may be unrelated, his anger about "going blind" and dissatisfaction with care suggests:

1. Inadequate ophthalmologic evaluation and management of his vision problem
2. Adjustment disorder or depression related to progressive vision loss that isn't being addressed
3. Possible medication contribution to visual symptoms (benzodiazepines cause eye movement disorders; multiple psychotropics affect vision) 2

The Trintellix 20 mg is FDA-approved for depression 3, not anxiety—if he truly has pure anxiety disorder, this may be suboptimal. However, his presentation (anger, dissatisfaction, hopelessness about vision) sounds more like depression with anxious distress related to medical illness.

Recommended Management Algorithm

Step 1: Reframe the Clinical Picture

• Stop treating this as refractory anxiety disorder. This is likely adjustment disorder with depressed mood secondary to vision loss, complicated by benzodiazepine dependence
• Obtain urgent ophthalmology consultation if not already done
• Screen for major depressive disorder—the Trintellix may be appropriate, but trazodone 25 mg is subtherapeutic for depression (FDA dosing starts at 150 mg/day in divided doses for depression) 4

Step 2: Optimize Antidepressant Therapy FIRST

• If depression is present: Consider increasing trazodone to therapeutic antidepressant doses (150-400 mg/day) 4 rather than using it as a hypnotic adjunct. This addresses both depression and sleep
• Alternative: Vortioxetine (Trintellix) 20 mg is already at maximum dose and shows efficacy by week 2-4 3. There is evidence it may be superior to other antidepressants in trauma-related depression 5
• Do not add more medications

Step 3: Initiate Benzodiazepine Taper

Following the EMPOWER trial approach 1:

• Educate the patient about benzodiazepine risks (cognitive impairment, falls, paradoxical anxiety worsening, addiction) and benefits of tapering
• Start with diazepam consolidation: Convert temazepam to equivalent diazepam dose, then taper the total daily diazepam by 25% every 1-2 weeks (slower than the cited weekly taper given his dual benzodiazepine use) 1
• Gradual reduction over many weeks to months is essential to avoid rebound/withdrawal 1
• Temazepam 15 mg ≈ diazepam 7.5 mg equivalent; if using nightly, total daily diazepam equivalent = ~17.5 mg

Step 4: Address Hydroxyzine Overuse

• Hydroxyzine 25 mg TID (75 mg/day total) used daily represents dependence on PRN medication
• Hydroxyzine has evidence for GAD (50 mg/day effective) 6 and doesn't interfere with antidepressants like benzodiazepines do 7
• Transition to scheduled dosing (25 mg BID or 50 mg QHS) rather than PRN to prevent clock-watching behavior
• As benzodiazepines taper and depression improves, hydroxyzine can be reduced

Step 5: Non-Pharmacologic Interventions

Per guidelines 1, pursue:

• Cognitive-behavioral therapy for anxiety and adjustment to vision loss
• Problem-solving therapy for disability adaptation
• Supportive psychotherapy addressing grief over vision loss
• Low vision rehabilitation services

Common Pitfalls to Avoid

1. Don't mistake benzodiazepine withdrawal/tolerance for worsening anxiety requiring more medication
2. Don't taper too quickly—this patient needs months, not weeks, given dual benzodiazepine exposure
3. Don't ignore the vision loss as the primary stressor driving his distress
4. Don't use trazodone 25 mg as a "sleep aid" when therapeutic antidepressant doses might address the core problem 4, 8

What to Tell the Patient

"Your current medications aren't working because we're treating the wrong problem. Your anxiety is related to losing your vision, and the benzodiazepines are actually making your brain function worse and possibly making you more anxious. We need to slowly reduce these medications over several months while better treating your depression and connecting you with vision specialists. Increasing doses will only make things worse and put you at risk for falls and memory problems. I'm going to work with you on a safer plan that actually addresses what's happening."

The evidence is clear: benzodiazepine escalation in this scenario increases morbidity and mortality risk without improving outcomes 1. Your refusal to escalate is medically appropriate and ethically necessary.